NASA compares October El Niño sea-height patterns with 1997
The satellite comparison shows a similar broad Pacific pattern. Similar-looking maps do not by themselves predict the same local weather outcomes.
Category: Science
Swift ends science observations, leaving an archive for future astronomy
NASA says Swift made its final observation on 20 October. Ending observations and predicting atmospheric re-entry are separate milestones.
Dragonfly completes a simulated first flight as Titan mission testing advances
The test combined flight software, avionics and simulated sensor inputs. It took place on Earth, not on Saturn’s moon Titan.
Artemis III plan puts Moon-lander rehearsals in Earth orbit before a 2028 landing
NASA’s 23 October plan describes a 2027 Earth-orbit test mission. Docking and operational demonstrations must come before a crewed lunar landing.
NASA safety panel schedules public review of ISS, commercial crew and Artemis
The panel’s 22 October meeting notice lists updates across human-spaceflight programmes. The agenda is an oversight step, not a certification or a published finding.
ESA brings rovers, robotics and astronaut outreach to Science Days in Germany
The 22–24 October programme in Rust links hands-on exhibits with European space science. Families should check the organiser’s visitor arrangements before travelling.
NASA’s Josephine image shows why an offshore storm can still affect the coast
NASA’s 22 October image feature documents Josephine’s cloud structure on 21 October. The image date, storm classification and current warnings are different pieces of information.
ESA ionosphere workshop reaches final scheduled day: why satellite signals matter
ESA’s 20–22 October workshop connects ionosphere research with navigation reliability. Here is what the science means—and what the event does not establish.
Novartis Faces Third Clinical-Trial Setback in a Week as Muscle Drug Fails
Novartis has encountered its third clinical trial failure in a week, as a muscle drug did not meet its primary endpoint in a late-stage study.
Novartis Encounters Third Clinical Trial Setback in a Week
Novartis has encountered its third clinical trial failure in a week, as a muscle drug did not meet its primary endpoint in a late-stage study.